New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 25, 2014
07:42 EDTBMYBristol-Myers shares set for a meaningful run, says Credit Suisse
Yesterday, Bristol-Myers stopped its Phase III CheckMate 066 study due to superior overall survival. Credit Suisse believes believes several other melanoma trials could stop early that 066 is positioned to be the first anti-PD1 agent approved ex-U.S. and that the FDA will likely accept it as well. The analyst believes Bristol-Myers shares are positioned for a meaningful run driven by immuno-oncology catalysts over the next 6-12 months and reiterates its Focus List Outperform rating and $59 price target.
News For BMY From The Last 14 Days
Check below for free stories on BMY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 22, 2014
07:21 EDTBMYEBD Group to hold a conference
Subscribe for More Information
September 17, 2014
07:43 EDTBMYBofA/Merrill to hold a conference
Subscribe for More Information
September 16, 2014
06:00 EDTBMYBristol-Myers announces Health Canada approval of Yervoy
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use